No Data
No Data
Sinolink Securities initiates coverage of Yidu Technology (02158) with a Buy rating and a Target Price of 7 Hong Kong dollars.
Sinolink recently released a research report on Yidu Technology (02158) for its first coverage, highlighting its core advantages and growth potential in the AI Medical field. Based on the accelerated promotion of its AI platform products and industry-leading data governance capabilities, a "Buy" rating is given with a Target Price of 7 Hong Kong dollars.
Yidu Technology (2158.HK): Collaborating with top hospitals + Deepening data governance AI-driven growth acceleration.
Investment logic Medical, as one of the most important AI application scenarios, is accelerating its commercialization process. By the end of 2024, a total of 46 companies nationwide have obtained filing for algorithms related to healthy living. Among many AI + Medical scenarios, AI + specialized assistance.
Yidu Technology assists Beizhong in creating the "CACA Guideline Assistant".
Yidu Tech Inc. Grants Share Awards to Drive Long-Term Growth
Yidu Technology (02158) awarded a total of 2.1393 million shares of incentive stock.
Yidu Technology (02158) announced that on March 28, 2025, the company will... according to the share issue after the initial public offering...
Yidu Technology has received a net Buy of over 30 million Hong Kong dollars from southbound funds for two consecutive days, and will participate in the national key research and development programs.
According to the latest data from Wind, on March 25, southbound funds net bought 3.6771 million shares of Yidu Technology, accounting for 23.97% of that day's Volume.